These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 8599036)
1. [Fenofibrate and arteriosclerosis. The new developments of the last 5 years]. Millán Núñez Cortés J; Alvarez-Sala Walther LA; de Oya Otero M Rev Clin Esp; 1995 Dec; 195(12):817-9. PubMed ID: 8599036 [No Abstract] [Full Text] [Related]
2. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044 [TBL] [Abstract][Full Text] [Related]
3. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD). Bailey CJ Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706 [No Abstract] [Full Text] [Related]
4. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129 [No Abstract] [Full Text] [Related]
5. [The effect of fenofibrate on the lipid level in diabetic patients]. Häring HU; Schleicher E; Renner R; Mehnert H MMW Munch Med Wochenschr; 1983 Sep; 125(35):751-3. PubMed ID: 6415427 [No Abstract] [Full Text] [Related]
8. Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits. Cardiovasc J Afr; 2007; 18(6):400. PubMed ID: 18092120 [No Abstract] [Full Text] [Related]
9. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid. Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186 [No Abstract] [Full Text] [Related]
12. [Systemic inflammatory process as an etiological factor in increase of atherogenic potential of plasma]. Ruban NV Fiziol Zh (1994); 2004; 50(2):64-74. PubMed ID: 15174207 [TBL] [Abstract][Full Text] [Related]
13. [Drug therapy of high risk patients with diabetes mellitus]. Krone W; Müller-Wieland D Verh Dtsch Ges Inn Med; 1991; 97():238-42. PubMed ID: 1808892 [No Abstract] [Full Text] [Related]
14. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia. Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157 [TBL] [Abstract][Full Text] [Related]
15. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Vergès B Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910 [TBL] [Abstract][Full Text] [Related]
16. [New studies: lipid regulation prevents development of atherosclerosis]. Olsson AG Lakartidningen; 1991 Jun; 88(25):2289-92. PubMed ID: 2062130 [No Abstract] [Full Text] [Related]
17. Clinical pharmacokinetics of fenofibrate. Telford M Curr Med Res Opin; 2003; 19(2):139; author reply 139-40. PubMed ID: 12740159 [No Abstract] [Full Text] [Related]
18. [The use of alisat for correction of level of lipids and their peroxidation products in blood of patients with atherosclerosis]. Mikhin VP Biull Eksp Biol Med; 1998 Sep; 126(9):345-9. PubMed ID: 9805629 [No Abstract] [Full Text] [Related]
19. [Modern treatment methods in atherosclerosis]. Aronov DM Ter Arkh; 1997; 69(11):75-81. PubMed ID: 9483757 [No Abstract] [Full Text] [Related]